Welcome to Guangzhou IGE Biotechnology Co., Ltd. Website !
Main Page > Services > MSI testing > Tumor microsatellite instability (MSI) testing

Tumor microsatellite instability (MSI) testing


        Microsatellites are short, tandemly repeated sequences that are scattered throughout the human genome. In tumor tissue, microsatellites can undergo insertions or deletions of repeat units, resulting in changes in microsatellite length. This phenomenon is called microsatellite instability (MSI).


        MSI is caused by defects in mismatch repair (MMR) genes. MMR genes are responsible for correcting errors in DNA replication. When MMR genes are defective, microsatellites are more likely to undergo insertions or deletions.


        MSI is an important prognostic factor for colorectal cancer. Patients with MSI-high (MSI-H) colorectal cancer have a worse prognosis than patients with MSI-low (MSI-L) or microsatellite stable (MSS) colorectal cancer. MSI-H colorectal cancer patients are also more likely to respond to immunotherapy drugs such as PD-1/PD-L1 inhibitors.


        MSI is also a diagnostic criterion for Lynch syndrome. Lynch syndrome is an autosomal dominant genetic disorder that is characterized by defects in MMR genes. Patients with Lynch syndrome are at increased risk for developing multiple cancers, including colorectal cancer, endometrial cancer, gastric cancer, and pancreatic cancer.



Clinically, MSI testing is used for the following purposes:


        To guide the use of PD-1/PD-L1 inhibitors in colorectal cancer patients


        To guide the choice of adjuvant treatment regimens in patients with stage II colorectal cancer


        To screen for Lynch syndrome


 

        Gold standard: The gold standard method for MSI testing is to use a first-generation sequencing platform to detect MSI status using an internationally recognized multiplex fluorescent PCR-capillary electrophoresis assay.


        Time: The test is a one-tube amplification assay that can be completed within 5 business days of sample receipt by the laboratory.


        Content: The test includes all single-nucleotide positions recommended by the National Cancer Institute (NCI), as well as additional positions that can be used to identify potential sample contamination or mix-ups, which can reduce the risk of errors.



未标题-1

图片9

图片10 








 


HotServices
020-89053723
Guangzhou IGE Biotechnology Co., Ltd.
Email: marketing@igebio.com
QQ: 1787730693
Address: Building G1-903, South China New Materials Innovation Park, #31 Kefeng Road, Huangpu Dist. Guangzhou, Guangdong prov. China 510663

Copyright © Guangzhou IGE Biotechnology Co., Ltd.
在线客服
  • 在线客服 send messages
  • Telphone:
  • 020-89053723
  • 在线客服